Drugs Made In America Acquisition II Corp. DMII FINANCIAL
Company Overview
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +2.88% |
| 6 Months: | +2.26% |
| 3 Months: | +0.84% |
| 1 Month: | +0.54% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)66.09 · Neutral
P/E of 35.03 is above the sector median of 12.89 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Financial Services).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DMII Drugs Made In America Acquisition II Corp. FINANCIAL | 10.16 | 35.03 | $647.19M | 0.00% | -0.10% | -23.56% | - | - |
| 2 | JPM JPMorgan Chase & Co. SPXR3KFINANCIAL | 353.51 | 15.15 | $939.70B | 1.72% | - | 17.79% | 12.50% | 14.83% |
| 3 | BRK-B Berkshire Hathaway Inc. SPXFINANCIAL | 505.83 | 12.72 | $712.23B | 0.00% | - | 12.12% | 4.18% | 9.44% |
| 4 | V Visa Inc. SPXR3KFINANCIAL | 368.64 | 31.35 | $628.20B | 0.72% | 37.15% | 61.19% | 14.33% | 13.04% |
| 5 | MA Mastercard Incorporated SPXR3KFINANCIAL | 570.89 | 31.44 | $496.37B | 0.62% | 60.19% | - | 12.29% | 19.21% |
| 6 | BAC Bank of America Corporation SPXR3KFINANCIAL | 62.39 | 14.41 | $436.28B | 2.04% | - | 11.20% | 3.14% | 4.27% |
| 7 | BRK-A Berkshire Hathaway Inc. FINANCIAL | 757,791.00 | 12.71 | $370.14B | 0.00% | - | 12.12% | 7.60% | 10.02% |
| 8 | HSBC HSBC Holdings plc FINANCIAL | 106.26 | 15.18 | $363.70B | 3.65% | - | 13.10% | 9.75% | 12.72% |
| 9 | MS Morgan Stanley SPXR3KFINANCIAL | 216.24 | 17.48 | $339.62B | 2.26% | - | 17.97% | 3.76% | 9.66% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Income | -59.33K | - | -155.51K | -132.03K |
| Net Income | -59.33K | -38.07K | -46.16K | 4.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Income | -488.38K |
| Net Income | 4.19M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 138.06K | 504.96M |
| Total Equity | -116.72K | -17.77M |
| Cash & Equivalents | - | 223 |
| Total Liabilities | 254.78K | 17.80M |
| Current Liabilities | 254.78K | 300.86K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Cash Flow | -1.02M |
| Investing Cash Flow | -500.00M |
| Financing Cash Flow | 501.00M |
| Capital Expenditure | - |
| Free Cash Flow | -1.02M |
| Net Change in Cash | -16.81K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2025 |
|---|---|
| Gross Margin % | - |
| Operating Margin % | - |
| Net Margin % | - |
| ROE % | -23.6% |
| ROCE % | -0.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Karpus Management, Inc. | 4.38% | 2.79M | $28.35M |
| 2 | MMCAP International, Inc. SPC | 4.24% | 2.70M | $27.46M |
| 3 | Magnetar Financial LLC | 4.24% | 2.70M | $27.46M |
| 4 | Glazer Capital LLC | 3.68% | 2.34M | $23.83M |
| 5 | Highbridge Capital Management, LLC. | 3.52% | 2.24M | $22.79M |
| 6 | Millennium Management Llc | 3.13% | 1.99M | $20.27M |
| 7 | Hudson Bay Capital Management Lp | 3.09% | 1.97M | $20.03M |
| 8 | Wolverine Asset Management, LLC | 2.91% | 1.86M | $18.87M |
| 9 | Polar Asset Management Partners Inc. | 2.35% | 1.50M | $15.26M |
| 10 | Tenor Capital Management Co., L.p. | 2.35% | 1.50M | $15.26M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DMII
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9PLVFSOXgyQmZrbFdmYThkRG5GaEhyaWVDYnZvaHBUZkNjaG0yVm1oR3gwZEo3LUt2MEFEVUZXWHkzRjdMU0llU3Q2Nl9hTE5X?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPdEFBc0VvWWNTR1FJd3ZKandwOGdOZXVUa3hReHpSVHNXMEdUdkVYZU1NLTlJM2pxbmlMR1cxdFJfNElReUYtaGd6aTYwd0w2Q1pVNEs3OG5ncjVqMXBxcG5zSDg0NG12aGV6RnhyNnVNQVExZ1hYeHhGLWtBVC1wa085a1ZHenJIOTV1Zk…
Benchmark initiates Tandem Diabetes stock with Hold on channel shift - Investing.com
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQZ3Ywb2F3SmtraWFlZnhzUzc0c1dGQjJWMjdyRlItMWpBZnJJc3VJTWVlOXVGenhyZXdlY2F0ZUJEX0VlV2dSVlhITTF1dTNlNmNKTDd5Mm1MTzRocXVfOTdNdzAxYl80X004ZUJqRHZjOUhqZFduUDNveHRwY0haM0o1S1RBV3k0eFgxbj…
Why Tandem Diabetes Care Stock Popped Today - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPQjZTSVhIaV9fTXkwZXI3WWR5amhFZDhFQ083UjN6eDRUNXpjZkdIVkFqZXFiZGFPUGcwbW9VTkpkYWxhaUo0VEpGRi1aWEtKOXZRcGxhdGVDUkVyUERteXF3bXVWS1lFYWNGcHVxXzZvYzNxQ2tKZUNXSjJmVndWbFRXaFhLbFFPSTh0MU…
DMII Stock Price and Chart — NASDAQ:DMII - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE0tei1fMmdvanZGOTBETzhMN2NIR3ZQYWNWSlJoZzQ5YlJPMm1GeHNBTDlZZzhfYWNIYlEtaEl0aXJjVXBROS1MejV4WG1XZi12ek5lRkc0OXJfbXRS?oc=5" target="_blank">DMII Stock Price and Chart — NASDAQ:DMII</a…
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOV2FwNzdub21QdnZaYkxidTFHa0VGeHUwRGROclRuNTRGcGtzNkNxRkhHeVJ5cEx1R05ubUhmLUVybDliTE1MRXQ4aWVvSnlCNE0xdWtkckNjME5hVm5KWTVrb0tQZXNLVnNjdS1PZExPU1lKbDZjUkV2Z1k4VW5DWlBNaXRncFVYRzduMl…
DMII — Frequently Asked Questions
What is the current share price of Drugs Made In America Acquisition II Corp. (DMII)?
As of 2026-09-19 21:16 PDT, Drugs Made In America Acquisition II Corp. (DMII) trades at $10.16 on NasdaqGM. Its 52-week range is $9.87 to $10.17.
What is the market capitalisation of DMII?
Drugs Made In America Acquisition II Corp. (DMII) has a market capitalisation of $647.19M on NasdaqGM.
What is the P/E ratio of DMII?
DMII trades at a trailing price-to-earnings (P/E) ratio of 35.03. The industry average P/E is 12.89. Its price-to-book (P/B) ratio is -36.16.
What is the return on equity (ROE) of DMII?
DMII has a return on equity (ROE) of -23.56%. Its return on capital employed (ROCE) is -0.10%.
Is DMII a good stock to buy?
This page provides a data-driven analysis of Drugs Made In America Acquisition II Corp. (DMII), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.